Compare Boeing Co (BA) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs ClearPoint Neuro Inc — how do they compare? Boeing Co trades at $217.9 (market cap $171.15B), while ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M). The key difference: Boeing Co is far larger — about 357.6× ClearPoint Neuro Inc's market cap, and Boeing Co pays a 0.03% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| BA | CLPT | |
|---|---|---|
Market Cap | $171.15B | $478.63M |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $29.60 |
52-Week Low | $179.12 | $8.66 |
Enterprise Value | $197.46B | $506.63M |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $215.51, down 3.05% on the day, amid a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 85.18 but improving revenue and net income, reaching $89.46B and $2.24B in 2025, respectively. Recent news highlights potential order wins, including discussions with Riyadh Air for additional 787s, while technical indicators point to support near $209.
Outlook remains cautiously optimistic with a consensus price target of $268.33, implying 24.5% upside, but risks include volatile cash flows, high debt, and ongoing operational challenges. Analyst sentiment is bullish with 66.7% buy ratings, though investors should monitor execution on delivery targets and margin improvements.
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
